Enterics for Global Health (Efgh): Shigella Surveillance Study

Loading...
Thumbnail Image
Date
2022-01-19
Journal Title
Journal ISSN
Volume Title
Publisher
Kamuzu University of Health Sciences
Abstract
Study type: The Enterics for Global Health (EFGH) Shigella surveillance study will employ crosssectional and longitudinal study designs to establish updated incidence rates and document consequences of Shigella diarrhea within 7 country sites in Africa, Asia, and Latin America. Problem: Diarrhea remains a leading cause of death among young children, with most diarrhea deaths occurring in low- and middle-income countries. Diarrhea caused by the bacterium Shigella is responsible for an estimated 60,000 deaths each year and may cause particularly severe illness among children. In low- and middle-income countries, nearly one third of children experience at least one episode of Shigella-attributable diarrhea during their first 2 years of life. In addition to it being a leading cause of diarrhea, this enteric bacterium is also associated with linear growth faltering, a precursor to stunting. Stunting is a marker of vulnerability to childhood infection, decreased vaccine efficacy and lifelong morbidity. Currently, there are several promising vaccines to prevent Shigella diarrhea in development, but key information is still needed to inform future vaccine studies. Broad objective: To determine the incidence of Shigella-attributed MAD in children 6 to 35 months of age. Specific objectives: 1) To determine the incidence of Shigella MAD by serotype, severity definition, laboratory method (culture vs. qPCR), age, and by season. 2) To describe the prevalence of resistance to commonly used antibiotics in Shigella isolates in each EFGH country site. 3) To determine the risk of death, hospitalization, persistent diarrhea, diarrhea recurrence, and linear growth faltering in the 3 months following an episode of Shigella MAD. 4) To compare various severity definitions in their ability to distinguish Shigella from non- Shigella attributable diarrhea, and their ability to predict risk of death or hospitalization in the subsequent 3 months following discharge from the health facility. 5) To qcuantify the cost incurred by families and health care systems due to Shigella morbidity and mortality. 6) To identify optimal laboratory methods for Shigella culture by comparing the isolation rate of Shigella between two transport media for rectal swabs (Cary-Blair and modified Buffered Glycerol Saline [BGS]) 7) To determine the serum immune responses to Shigella infection, utilizing acute and convalescent blood samples. Methodology: Over a two-year period, the EFGH study will enroll 9,800 children (1,400 per country site) between 6-35 months of age with MAD. In Malawi, the population under surveillance will comprise residents of Ndirande Township, with children recruited from Ndirande District Health Centre. and the Queen Elizabeth Central Hospital, Blantyre. Population enumeration and healthcare utilization studies will be undertaken to inform Shigella-attributed MAD incidence estimates. A stool sample will be obtained from each child on enrolment and examined for Shigella by culture and qPCR. Acute and convalescent dried blood spot samples will be examined for Shigella antibody using ELISA. Children will be followed following discharge for three months to allow assessment of clinical outcomes, growth, and costs attributed to Shigella infection. Expected Results and Dissemination: Eventual Phase 2b/3 Shigella vaccine trials will require a consortium of potential vaccine trial sites in settings with a high incidence of Shigella-attributed MAD, high participant retention, and the laboratory capacity to confirm Shigella infection. Through this multi-country surveillance network, selected EFGH sites will be ready to quickly implement rigorous and efficient vaccine trials and provide critical data to policy makers about the relative importance of this vaccine-preventable disease, accelerating the time to vaccine availability and uptake among children in high Shigella burden settings. The study findings will be shared with the College of Medicine Research Ethics Committee (COMREC), the Ministry of Health (MoH), published in peer reviewed journals and will be disseminated to the public through the annual College of Medicine Research dissemination conference.
Description
Keywords
Incidences of diarrhea
Citation
Collections